This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab every 4 weeks and ipilimumab every 8 weeks until disease progression, unacceptable toxicity, or 2 years of therapy.

You may be eligible for this study if you meet the following criteria:

• Conditions: Colorectal cancer
• Age: 99 years or below
• Gender: All